Seminars in Oncology
Volume 35, Issue 3 , Pages 251-261, June 2008

Concurrent Chemotherapy and Re-irradiation for Locoregionally Recurrent Head and Neck Cancer

  • Joseph K. Salama

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL.
    • Cancer Research Center, University of Chicago, Chicago, IL.
    • Corresponding Author InformationAddress correspondence to Joseph K. Salama, MD, Department of Radiation and Cellular Oncology, 5758 S Maryland Ave, MC 9006, Chicago, IL 60637.
  • ,
  • Everett E. Vokes

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL.
    • Cancer Research Center, University of Chicago, Chicago, IL.
    • Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.

Recurrent and second primary tumors arising within a previously radiated head and neck volume represent a difficult clinical scenario to manage. For patients who have resectable disease, surgery is the standard treatment. Chemotherapy is the standard for patients with unresectable or metastatic disease but offers no chance for cure. Re-irradiation (RRT) with concurrent chemotherapy is a potentially curative treatment option. In this article, we will review the basis for current chemoradiotherapy (CRT) regimens used in previously radiated patients, focusing on outcome and toxicity. Additionally, we will review radiotherapy techniques used in this setting and highlight the differences between definitive radiotherapy and RRT. Controversies, such as the utility of chemotherapy and RRT following surgical salvage, will be addressed. Finally, we will review investigations seeking to improve the therapeutic outcomes of patients treated with chemotherapy and RRT.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(08)00073-0

doi:10.1053/j.seminoncol.2008.03.010

Seminars in Oncology
Volume 35, Issue 3 , Pages 251-261, June 2008